Advertisement

Drug Safety

, Volume 35, Supplement 1, pp 73–87 | Cite as

The Economic Burden of Inappropriate Drug Prescribing, Lack of Adherence and Compliance, Adverse Drug Events in Older People

A Systematic Review
  • Carlos Chiatti
  • Silvia BustacchiniEmail author
  • Gianluca Furneri
  • Lorenzo Mantovani
  • Marco Cristiani
  • Clementina Misuraca
  • Fabrizia Lattanzio
Review Article

Abstract

Adverse drug events (ADEs) are an increasingly relevant issue for healthcare systems as they are associated with poorer health outcomes and avoidable misuse of resources. The rates of ADEs are higher in the elderly population, as many older patients have comorbidities, multiple drug prescriptions and deteriorated physical and cognitive functioning. The occurrence of ADEs can lead to a perceived lack of therapy efficacy and further underuse or suboptimal adherence in elderly people, with detrimental clinical outcomes. The present article systematically reviews the studies evaluating the economic impact of ADEs occurring as consequence of poor therapy adherence, inappropriate drug use, underuse of effective treatments and poor adherence, medication errors, drug-drug and drug-disease interactions.

A Medline systematic literature review of studies evaluating the economic consequences of inappropriate drug prescribing, lack of adherence and compliance, ADEs in older people was performed. English-language articles were screened through a three-step approach (title review, abstract review, full article review) to select pertinent studies quantitatively evaluating costs. We systematically reviewed evidence from767 articles. After title, abstract and full text review, 21 articles were found to measure economic implications ofADEs, inappropriate drug prescribing and poor adherence in elderly patients. Studies suggested that the economic impact of these undesired effects is substantial: hospital costs were the main cost driver, with a relevant part of them being preventable (consequences of inappropriate prescribing). Healthcare costs for unused drug wastage and destruction were also surprisingly high.

Although economic evidence in elderly patients is still limited, all studies seemed to confirm that the financial burden due to pharmacological treatment issues is relevant in elderly people. Including economic effects of adverse events in pharmacoeconomic analysis would be beneficial to improve the reliability of results. Preliminary evidence suggests that programmes aimed at comprehensively assessing geriatric conditions, detecting ‘high-risk’ prescriptions and training patients to comply with prescribed therapies could be costeffective measures to reduce the burden of ADEs.

Keywords

Androgen Deprivation Therapy Adverse Drug Event Inappropriate Medication Inappropriate Prescribe Full Text Review 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lutz W, Sanderson W, Scherbov S. The coming acceleration of global population ageing. Nature 2008 Feb 7; 451 (7179): 716–19PubMedCrossRefGoogle Scholar
  2. 2.
    Crimmins EM, Hayward MD, Hagedorn A, et al. Change in disability-free life expectancy for Americans 70 years old and older. Demography 2009 Aug; 46 (3): 627–46PubMedCrossRefGoogle Scholar
  3. 3.
    Chernew ME, Hirth RA, Cutler DM. Increased spending on health care: long-term implications for the nation. Health Aff (Millwood) 2009 Sep–Oct; 28 (5): 1253–5CrossRefGoogle Scholar
  4. 4.
    Bech M, Christiansen T, Khoman E, et al. Ageing and health care expenditure in EU-15. Eur J Health Econ 2011 Oct; 12 (5): 469–78PubMedCrossRefGoogle Scholar
  5. 5.
    Herwartz H, Theilen B. The determinants of health-care expenditure: new results from semiparametric estimation. Health Econ 2010 Aug; 19 (8): 964–78PubMedCrossRefGoogle Scholar
  6. 6.
    Dormont B, Grignon M, Huber H. Health expenditure growth: reassessing the threat of ageing. Health Econ 2006 Sep; 15 (9): 947–63CrossRefGoogle Scholar
  7. 7.
    Fernández-Olano C, Hidalgo JD, Cerdá-Díaz R, et al. Factors associated with health care utilization by the elderly in a public health care system. Health Policy 2006 Jan; 75 (2): 131–9PubMedCrossRefGoogle Scholar
  8. 8.
    Saver BG, Doescher MP, Jackson JE, et al. Seniors with chronic health conditions and prescription drugs: benefits, wealth, and health. Value Health 2004 Mar–Apr; 7 (2): 133–43PubMedCrossRefGoogle Scholar
  9. 9.
    Johnell K, Fastbom J, Rosén M, et al. Inappropriate drug use in the elderly: a nationwide register-based study. Ann Pharmacother 2007 Jul; 41 (7): 1243–8PubMedCrossRefGoogle Scholar
  10. 10.
    Opondo D, Eslami S, Visscher S, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS One 2012; 7 (8): e43617PubMedCrossRefGoogle Scholar
  11. 11.
    Bainbridge JL, Ruscin JM. Challenges of treatment adherence in older patients with Parkinson’s disease. Drugs Aging 2009; 26 (2): 145–55PubMedCrossRefGoogle Scholar
  12. 12.
    Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002 Jul 24–31; 288 (4): 462–7PubMedCrossRefGoogle Scholar
  13. 13.
    Fialová D, Onder G. Medication errors in elderly people: contributing factors and future perspectives. Br J Clin Pharmacol 2009 June; 67 (6): 641–5PubMedCrossRefGoogle Scholar
  14. 14.
    Zakharov S, Tomas N, Pelclova D. Medication errors-an enduring problem for children and elderly patients. Ups J Med Sci 2012 Aug; 117 (3): 309–17PubMedCrossRefGoogle Scholar
  15. 15.
    Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600 000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 2007; 30 (10): 911–18PubMedCrossRefGoogle Scholar
  16. 16.
    Bacic-Vrca V, Marusic S, Erdeljic V, et al. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci 2010 Dec; 32 (6): 815–21PubMedCrossRefGoogle Scholar
  17. 17.
    Kojima T, Akishita M, Kameyama Y, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int 2012 Oct; 12 (4): 761–2PubMedCrossRefGoogle Scholar
  18. 18.
    Sera LC, McPherson ML. Pharmacokinetics and pharmacodynamic changes associated with aging and implications for drug therapy. Clin Geriatr Med 2012 May; 28 (2): 273–86PubMedCrossRefGoogle Scholar
  19. 19.
    Shi S, Mörike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol 2008 Feb; 64 (2): 183–99PubMedCrossRefGoogle Scholar
  20. 20.
    Corsonello A, Pedone C, Corica F, et al., Gruppo Italiano di Farmacovigilanza nell-Anziano (GIFA) Investigators. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005 Apr 11; 165 (7): 790–5PubMedCrossRefGoogle Scholar
  21. 21.
    Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011 Nov 24; 365 (21): 2002–12PubMedCrossRefGoogle Scholar
  22. 22.
    Budnitz DS, Shehab N, Kegler SR, et al. Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 2007 Dec 4; 147 (11): 755–65PubMedGoogle Scholar
  23. 23.
    Mjörndal T, Boman MD, Hägg S, et al. Adverse drug reactions as a cause for admissions to a department of internal medicine. Pharmacoepidemiol Drug Saf 2002 Jan–Feb; 11 (1): 65–72PubMedCrossRefGoogle Scholar
  24. 24.
    Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003 Mar 5; 289 (9): 1107–16PubMedCrossRefGoogle Scholar
  25. 25.
    Swedish National Institute of Public Health (SNIPH) (2007), Healthy Ageing: a Challenge for Europe, Brussels [Stockholm], http://www.healthyageing.nu Google Scholar
  26. 26.
    Fick DM, Mion LC, Beers MH, et al. Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health 2008 Feb; 31 (1): 42–51PubMedCrossRefGoogle Scholar
  27. 27.
    Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging 2004; 21 (12): 793–811PubMedCrossRefGoogle Scholar
  28. 28.
    Munger MA, Van Tassell BW, LaFleur J. Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed 2007 Sep 19; 9 (3): 58PubMedGoogle Scholar
  29. 29.
    Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and metaanalysis. Osteoporos Int 2010 Nov; 21 (11): 1943–51PubMedCrossRefGoogle Scholar
  30. 30.
    Kusserow RP. Medication Regimens: Causes of Noncompliance. Washington, DC: Office of Inspector General, U.S. Department of Health and Human Services; 1990. WOEI-04-89-8912Google Scholar
  31. 31.
    Sullivan SD, Krelig DH, Hazlet TK. Noncompliance with medical regimens and subsequent hospitalization: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ 1990; 2: 19–33Google Scholar
  32. 32.
    Hughes DA, Bagust A, Haycox A, et al. The impact of noncompliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001 Oct; 10 (7): 601–15PubMedCrossRefGoogle Scholar
  33. 33.
    Hughes DA, Bagust A, Haycox A, et al. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001; 19 (12): 1185–97PubMedCrossRefGoogle Scholar
  34. 34.
    Kale A, Keohane CA, Maviglia S, et al. Adverse drug events caused by serious medication administration errors. BMJ Qual Saf 2012 Nov; 21 (11): 933–8PubMedCrossRefGoogle Scholar
  35. 35.
    Klopotowska JE, Wierenga PC, Smorenburg SM, et al.; on behalf of the WINGS study group. Recognition of adverse drug events in older hospitalized medical patients. Eur J Clin Pharmacol 2012 Jun 7 [Epub ahead of print]Google Scholar
  36. 36.
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009 Oct; 62(10): e1–34PubMedCrossRefGoogle Scholar
  37. 37.
    Pérez Menéndez-Conde C, Bermejo Vicedo T, Delgado Silveira E, et al. Adverse drug reactions which provoke hospital admission. Farm Hosp 2011 Sep–Oct; 35 (5): 236–43PubMedCrossRefGoogle Scholar
  38. 38.
    Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting. Am J Manag Care 2010 Sep; 16 (9): e228–34PubMedGoogle Scholar
  39. 39.
    Hoonhout LH, de Bruijne MC, Wagner C, et al. Nature, occurrence and consequences of medication-related adverse events during hospitalization: a retrospective chart review in the Netherlands. Drug Saf 2010 Oct 1; 33 (10): 853–64PubMedCrossRefGoogle Scholar
  40. 40.
    Manson SC, Benedict A, Pan F, et al. Potential economic impact of increasing low dose aspirin usage on CVD in the USA. Curr Med Res Opin 2010 Oct; 26 (10): 2365–73PubMedCrossRefGoogle Scholar
  41. 41.
    Doggrell SA. Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help? Drugs Aging 2010 Mar 1; 27 (3): 239–54PubMedCrossRefGoogle Scholar
  42. 42.
    Pratt N, Roughead EE, Ryan P, et al. Differential impact of NSAIDs on rate of adverse events that require hospitalization in high-risk and general veteran populations: a retrospective cohort study. Drugs Aging 2010 Jan 1; 27 (1): 63–71PubMedCrossRefGoogle Scholar
  43. 43.
    Broyles RW, Chou AF, Mattachione S, et al. The effect of adverse medical events on spending on inpatient care. Qual Manag Health Care 2009 Oct–Dec; 18 (4): 315–25PubMedGoogle Scholar
  44. 44.
    Volpe M, Chin D, Paneni F. The challenge of polypharmacy in cardiovascular medicine. Fundam Clin Pharmacol 2010 Feb; 24 (1): 9–17PubMedCrossRefGoogle Scholar
  45. 45.
    Ryan C, O’Mahony D, Kennedy J, et al. Appropriate prescribing in the elderly: an investigation of two screening tools, Beers criteria considering diagnosis and independent of diagnosis and improved prescribing in the elderly tool to identify inappropriate use of medicines in the elderly in primary care in Ireland. J Clin Pharm Ther 2009 Aug; 34 (4): 369–76PubMedCrossRefGoogle Scholar
  46. 46.
    Chapman RH, Petrilla AA, Benner JS, et al. Predictors of adherence to concomitant antihypertensive and lipidlowering medications in older adults: a retrospective, cohort study. Drugs Aging 2008; 25 (10): 885–92PubMedCrossRefGoogle Scholar
  47. 47.
    van der Velde N, Meerding WJ, Looman CW, et al. Cost effectiveness of withdrawal of fall-risk-increasing drugs in geriatric outpatients. Drugs Aging 2008; 25 (6): 521–9PubMedCrossRefGoogle Scholar
  48. 48.
    Krupski TL, Foley KA, Baser O, et al. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications. J Urol 2007 Oct; 178 (4 Pt 1): 1423–8PubMedCrossRefGoogle Scholar
  49. 49.
    Rocchiccioli JT, Sanford J, Caplinger B. Polymedicine and aging. Enhancing older adult care through advanced practitioners. GNPs and elder care pharmacists can help provide optimal pharmaceutical care. J Gerontol Nurs 2007 Jul; 33 (7): 19–24PubMedGoogle Scholar
  50. 50.
    Tinetti ME, Gordon C, Sogolow E, et al. Fall-risk evaluation and management: challenges in adopting geriatric care practices. Gerontologist 2006 Dec; 46 (6): 717–25PubMedCrossRefGoogle Scholar
  51. 51.
    Nickel JC. BPH: costs and treatment outcomes. Am J Manag Care 2006 Apr; 12 (5 Suppl.): S141–8PubMedGoogle Scholar
  52. 52.
    Fuhlbrigge AL, Bae SJ, Weiss ST, et al. Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density. J Allergy Clin Immunol 2006 Feb; 117 (2): 359–66PubMedCrossRefGoogle Scholar
  53. 53.
    Morant SV, McMahon AD, Cleland JG, et al. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004 Feb; 57 (2): 188–98Google Scholar
  54. 54.
    Solomon DH, Glynn RJ, Bohn R, et al. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients. J Rheumatol 2003 Apr; 30 (4): 792–8PubMedGoogle Scholar
  55. 55.
    von Gunten V, Reymond JP, Boubaker K, et al. Antibiotic use: is appropriateness expensive? J Hosp Infect 2009 Feb; 71 (2): 108–11CrossRefGoogle Scholar
  56. 56.
    Wu C, Bell CM, Wodchis WP. Incidence and economic burden of adverse drug reactions among elderly patients in Ontario emergency departments: a retrospective study. Drug Saf 2012 Sep 1; 35 (9): 769–81PubMedGoogle Scholar
  57. 57.
    Field TS, Gilman BH, Subramanian S, et al. The costs associated with adverse drug events among older adults in the ambulatory setting. Med Care 2005 Dec; 43 (12): 1171–6PubMedCrossRefGoogle Scholar
  58. 58.
    Anderson WK, Wahler R. Forum. Pharmacy management can reduce Medicare — and human costs. Aging today 2001; 22 (1): 3–8Google Scholar
  59. 59.
    Campbell NL, Boustani MA, Skopelja EN, et al. Medication adherence in older adults with cognitive impairment: a systematic evidence-based review. Am J Geriatr Pharmacother 2012 Jun; 10 (3): 165–77PubMedCrossRefGoogle Scholar
  60. 60.
    Sengstock D, Vaitkevicius P, Salama A, et al. Underprescribing and non-adherence to medications after coronary bypass surgery in older adults: strategies to improve adherence. Drugs Aging 2012 Feb 1; 29 (2): 93–103PubMedCrossRefGoogle Scholar
  61. 61.
    Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medicine adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003; 25: 2958–71PubMedCrossRefGoogle Scholar
  62. 62.
    Balkrishnan R, Bhosle MJ, Camacho FT, et al. Predictors of medicine adherence and associated health care costs in an older population with overactive bladder syndrome: a longitudinal cohort study. J Urol 2006; 175: 1067–71PubMedCrossRefGoogle Scholar
  63. 63.
    Isacson D, Olofsson C. Drugs up in smoke: a study of caseated drugs in Sweden. Pharm World Sci 1999; 21: 96–9PubMedCrossRefGoogle Scholar
  64. 64.
    Safran DG, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: how well are States closing the gap? Health Aff (Millwood) 2002 Jul–Dec; Suppl Web Exclusives: W253–68Google Scholar
  65. 65.
    Lyman GH, Kuderer NM, Crawford J, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011 May 1; 117 (9): 1917–27PubMedCrossRefGoogle Scholar
  66. 66.
    Badalamenti VC, Buckley JW, Smith ET. Safety of EMBEda (morphine sulfate and naltrexone hydrochloride) extendedrelease capsules: review of postmarketing adverse events during the first year. J Opioid Manag 2012 Mar–Apr; 8 (2): 115–25PubMedCrossRefGoogle Scholar
  67. 67.
    Brajovic S, Piazza-Hepp T, Swartz L, et al. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration. Pharmacoepidemiol Drug Saf 2012 Jun; 21 (6): 565–70; discussion 571–2PubMedCrossRefGoogle Scholar
  68. 68.
    Hakobyan L, Haaijer-Ruskamp FM, de Zeeuw D, et al. Comparing adverse event rates of oral blood glucoselowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011. Drug Saf 2011 Dec 1; 34 (12): 1191–202PubMedCrossRefGoogle Scholar
  69. 69.
    World Health Organization 2002. The Importance of Pharmacovigilance. Safety monitoring of medicinal products. Available at URL: http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf [Accessed August 23, 2012]Google Scholar
  70. 70.
    Suh DC, Woodall BS, Shin SK, et al. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000 Dec; 34 (12): 1373–9PubMedCrossRefGoogle Scholar
  71. 71.
    White TJ, Arakelian A, Rho JP. Counting the costs of drugrelated adverse events. Pharmacoeconomics 1999 May; 15 (5): 445–58PubMedCrossRefGoogle Scholar
  72. 72.
    Crome P, Lally F, Cherubini A, et al. Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study. Drugs Aging 2011 Aug 1; 28 (8): 667–77PubMedCrossRefGoogle Scholar
  73. 73.
    Smith SR, Rublein JC, Marcus C, et al. A medication selfmanagement program to improve adherence to HIV therapy regimens. Patient Educ Couns 2003 Jun; 50 (2): 187–99PubMedCrossRefGoogle Scholar
  74. 74.
    Campbell RK. Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing insulin- based therapy. Am J Manag Care 2012 Apr; 18 (3 Suppl.): S55–61PubMedGoogle Scholar
  75. 75.
    American Pharmacists Association; National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). 2008. Available at url: http://www.accp.com/docs/positions/misc/CoreElements.pdf. [Accessed August 23, 2012]Google Scholar
  76. 76.
    Gonzalez J, Noga M. Medication therapy management. J Manag Care Pharm 2008; 14 (6 Suppl. S-c): S8–11Google Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Carlos Chiatti
    • 1
  • Silvia Bustacchini
    • 1
    Email author
  • Gianluca Furneri
    • 1
  • Lorenzo Mantovani
    • 2
  • Marco Cristiani
    • 3
  • Clementina Misuraca
    • 4
  • Fabrizia Lattanzio
    • 1
  1. 1.Scientific DirectionItalian National Research Center on Aging (INRCA)AnconaItaly
  2. 2.Faculty of PharmacyFederico II University of NaplesNaplesItaly
  3. 3.Charta FoundationMilanItaly
  4. 4.Unit of Pulmonary Rehabilitation, Research Hospital of CasatenovoItalian National Research Center on Aging (INRCA)CasatenovoItaly

Personalised recommendations